United Kingdom · Medical devices startup
United Kingdom · Phagenesis
Phagenesis Ltd. is a UK-based medical technology company founded in 2007, focused on developing non-surgical neurostimulation therapies for neurogenic dysphagia, particularly in pa
Funding reportedLast round: Series D
About Phagenesis
Phagenesis Ltd. is a UK-based medical technology company founded in 2007, focused on developing non-surgical neurostimulation therapies for neurogenic dysphagia, particularly in pa
tients recovering from stroke or neurological injuries. The company is headquartered in Manchester and operates as a subsidiary of Nestlé Health Science. Led by CEO Reinhard Krickl, Phagenesis employs around 47 people and is dedicated to improving patient recovery and reducing healthcare burdens. The core product, the Phagenyx® Neurostimulation System, is the first therapy to deliver targeted pharyngeal electrical stimulation to restore safe swallowing. This non-invasive device stimulates nerves in the pharynx, leveraging the brain's neuroplasticity to regain control of swallowing functions. Supported by over 20 years of research and extensive clinical evidence, the system enhances swallowing safety and efficiency, accelerates recovery from dysphagia, and integrates into care protocols for stroke rehabilitation and neurocritical care. Phagenesis primarily serves healthcare providers, including stroke rehabilitation centers and speech-language pathology clinics, aiming to improve outcomes for patients with swallowing impairments.
What company datasets say Phagenesis raised
Funding, as reported
Funding filed with regulators
Phagenesis filed 3 raises, $39M in all. Filings say how much was sold and to how many investors; they never name the investors.
- Apr 2026$12MUK share allotment
- Aug 2025$13MUK share allotment
- Aug 2024$14MUK share allotment
Founders and team
From Phagenesis's own website: 2 founders, 19 on the team.
- Andre NelChief Financial Officer
- Marc KorenbergChief Financial Officer
- Anil KeniVP Global Marketing
- Buck WellerVP Sales, US
- Cari ManypennyHead of Global Education
- Maddy SadiqHead of Human Resources
- Nick WoodcockVP Sales, Europe
- Scott GrantVP US Therapy Development
- Stephen HalsteadHead of QA/RA
- Boris DeutschmannDirector European Sales
- Chad HoskinsDirector
- Drew BurdonDirector
- Fred EdeniusDirector
- Independent AdvisorDirector
- James GibbonsDirector
- Michael SjöströmDirector
- Michel GardetDirector
- Oern StugeChairperson, Director
And 1 more on the team.
On 2 portfolio pages
Investors who name them
Each firm lists Phagenesis on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
cortical reorganizationnon-surgical therapybrain injury recoveryhealth caresensorimotor cortexmedical device regulationneurostimulationdistributionmanufacturinglong-term cortex reorganizationreal-world datadysphagia therapypersonalized therapyneuroplasticitypharyngeal electrical stimulationneurostimulation in icu
Built with from their website
Salesforce CRM AnalyticsWP EngineHubspotBarracuda MSPMicrosoft ExchangeSalesforceMySQLMicrosoft 365 Apps & ServicesGreenhouseFasthosts
+8 more
Anthropic ClaudeBarracuda Email Security ServiceBarracuda NetworksWordpressMicrosoft Exchange OnlineMicrosoft 365OutlookPHP
- Sector
- Medical devices
- Industry code
- NAICS 33911, 334510, SIC 3844, 3841
- Region
- England
- Part of
- Nestlé Health Science
- Revenue
- 4.3M a year, as listed
- Full record
- Every detail in the company directory
Medical devices in United Kingdom
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Phagenesis in front of investors. Or tell us what we have wrong.